TrialBreast cancer research : BCR2023

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

P Neven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.